Table 1.
Characteristics of Patients in Cohort 1. Patients with documented reactions to PEG and polysorbate in the EMR before receiving COVID-19 vaccines did not have documented reactions to the COVID-19 vaccine. Patients could have more than one PEG or polysorbate reaction documented as shown in "Documented Reactions(s)", resulting in a combined total percentage of individual allergens >100%.
| Characteristics | Received COVID-19 vaccine (n = 202) |
|---|---|
| Age in y, median (range) | 75 (14-93) |
| Female sex at birth, n (%) | 147 (73) |
| Race and Ethnicity, n (%) White Hispanic or Latino Black Asian American Indian Multiracial Other or unknown |
137 (68) 13 (6) 7 (4) 33 (16) — — 12 (6) |
| Documented reaction(s), n (%) 1 PEG allergen 1 Polysorbate allergen 2 PEG allergens 2 Polysorbate allergens 1 PEG, 1 polysorbate allergen Propylene glycol |
34 (17) 150 (74) 2 (1) 10 (5) 2 (1) 4 (2) |
| # PEG allergens, n (%) Bimatoprost (PEG, unspecified) Doxorubicina (PEG 2000) Methylprednisolone acetate (PEG 3350) Neulasta (20-kD monomethoxy PEG) PEG, unspecified type PEG 300 PEG 400 PEG 3350 PEG-asparaginase (PEG 5000) Perflutren (PEG 5000) Trastuzumab (PEG 3350) |
39 (19) 8 (4) 4 (2) 1 (0) 2 (1) 10 (5) 1 (0) 2 (1) 4 (2) 3 (1) 1 (0) 3 (1) |
| # Polysorbate allergens, n (%) Influenza vaccine, unspecified type Influenza quadrivalent vaccine (polysorbate 80) Hepatitis A vaccine (polysorbate 20) Pneumococcal vaccine, unspecified type Pneumococcal conjugated vaccine (Prevnar 13) (polysorbate 80) Tetanus vaccine (polysorbate 80) Zoster vaccine (polysorbate 80) |
172 (85) 47 (23) 5 (2) 2 (1) 17 (8) 12 (6) 66 (33) 23 (11) |
| Documented reaction symptoms, n (%) Anaphylaxis Cutaneous Respiratory Neurologic Gastrointestinal Other/unknown Missing |
9 (4) 72 (36) 1 (0) 1 (0) 7 (3) 21 (10) 105 (52) |
Abbreviations: COVID-19, coronavirus disease 2019; EMR, electronic medical record; PEG, polyethylene glycol.
Note: The bolded n (%) indicate total n (%) for all PEG allergens and all polysorbate allergens.
a
Included as doxorubicin can be PEGylated in liposomal form.